Jim Tananbaum (Foresite Capital)
April 18, 2022 11:14 AM EDT
Financing

Fore­site's Jim Tanan­baum yanks $250M SPAC, as an RA-backed Ox­ford spin­out braves the chop­py IPO wa­ters

Max Gelman

Senior Editor

The biotech mar­ket con­di­tions have ap­par­ent­ly got­ten chop­py enough to now pre­clude SPAC di­rec­tors from tak­ing their blank check com­pa­nies pub­lic.

Jim Tanan­baum’s Fore­site Cap­i­tal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times